---
search:
  boost: 3
---

# Osteoporosis â€“ Bone Ossification Enhancers

This is a subcategory of Endocrine Agents.

## Decision Trees

- [Endocrine - Osteoporosis - Alendronate Susp, Fosamax Plus D, Risedronate](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUODZTREFZRjc1RFE5QkRQSTUyNlo2UVFIUiQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

- [Endocrine - Osteoporosis - Forteo](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURUIxVVpFNzZDMFJXTTIzRU80WVU0OU1DTiQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

- [Endocrine - Osteoporosis - Tymlos](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQjJYTDdRTzBEWUgwVDQ5WEU5N1dXQUtMTyQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred            | Generic Name                                   | Quantity | Time (Days) |
| :------------------- | :--------------------------------------------- | :------: | :---------: |
| Alendronate Tab      |                                                |          |             |
| Calcitonin-Salmon    |                                                |          |             |
| Forteo <sup>PA QL</sup> | Teriparatide Subcutaneous Inj 600 MCG / 2.4 ML |   62.4   |     730     |
| Ibandronate          |                                                |          |             |

### Non-Preferred

| Non-Preferred        | Generic Name                                        |         Quantity          |        Time (Days)        |
| :------------------- | :-------------------------------------------------- | :-----------------------: | :-----------------------: |
| Alendronate Susp     |                                                     |                           |                           |
| Fosamax Plus D       |                                                     |                           |                           |
| Risedronate          |                                                     |                           |                           |
| Tymlos <sup>QL</sup> | Abaloparatide Soln Subcutaneous Inj (all strengths) | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Teriparatide (Forteo<sup>TM</sup>)

Teriparatide (Forteo<sup>TM</sup>) Criteria

- Must have had an inadequate clinical response of at least ^^365 days^^ with ^^one^^ bisphosphonate
- A total lifetime duration of therapy of 730 days will be authorized between any parathyroid analog

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^365 days^^ with at least ^^one preferred^^ drug within the same class
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Abaloparatide (Tymlos<sup>TM</sup>)

Additional Abaloparatide (Tymlos<sup>TM</sup>) Criteria

- Must have had an inadequate clinical response of at least ^^365 days^^ with ^^one^^ bisphosphonate
- A total lifetime duration of therapy of 730 days will be authorized between any parathyroid analog

### Additional Information

- Patients should only be on ONE of the therapeutic classes (bisphosphonates, calcitonin-salmon)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=61){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=22){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
